Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accumulated Expenses (2016 - 2025)

RedHill Biopharma has reported Accumulated Expenses over the past 10 years, most recently at $12.0 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 20.24% to $12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, up 20.24% year-over-year, with the annual reading at $12.0 million for FY2025, 20.24% up from the prior year.
  • Accumulated Expenses was $12.0 million for Q4 2025 at RedHill Biopharma, up from $10.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $25.4 million in Q1 2021 and troughed at $4.0 million in Q2 2024.
  • The 5-year median for Accumulated Expenses is $17.9 million (2022), against an average of $16.0 million.
  • Year-over-year, Accumulated Expenses plummeted 74.42% in 2023 and then skyrocketed 169.78% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $20.9 million in 2021, then dropped by 14.1% to $17.9 million in 2022, then plummeted by 74.42% to $4.6 million in 2023, then soared by 117.62% to $10.0 million in 2024, then rose by 20.24% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Accumulated Expenses are $12.0 million (Q4 2025), $10.7 million (Q2 2025), and $10.0 million (Q4 2024).